Market Closed -
Nyse
10:04:16 2024-03-20 am EDT
|
5-day change
|
1st Jan Change
|
0.0198
USD
|
+1,979,900.00%
|
|
+1,299,900.00%
|
-99.61%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
---|
Capitalization
1 |
350.2
|
343.6
|
21.21
|
Enterprise Value (EV)
1 |
314.5
|
381.5
|
76.06
|
P/E ratio
|
-0.58
x
|
-0.12
x
|
-0.21
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
16,331,266
x
|
30,721,502
x
|
823,104
x
|
EV / Revenue
|
14,667,009
x
|
34,107,465
x
|
2,951,835
x
|
EV / EBITDA
|
-12.4
x
|
-4.7
x
|
-0.65
x
|
EV / FCF
|
-5,818,178
x
|
-14,472,039
x
|
-1,297,882
x
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
Price to Book
|
-0.15
x
|
-0.07
x
|
-0.85
x
|
Nbr of stocks (in thousands)
|
34,500
|
34,500
|
73,034
|
Reference price
2 |
10.15
|
9.960
|
0.2904
|
Announcement Date
|
11/9/21
|
5/24/22
|
3/28/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
21.44
|
11.18
|
25.77
|
EBITDA
1 |
-29.62
|
-25.45
|
-81.18
|
-116.3
|
EBIT
1 |
-31.21
|
-28.22
|
-84.97
|
-121.8
|
Operating Margin
|
-
|
-131.63%
|
-759.7%
|
-472.72%
|
Earnings before Tax (EBT)
1 |
-28.37
|
-23.87
|
-93.33
|
-55.3
|
Net income
1 |
-22.96
|
-25.9
|
-93.35
|
-55.78
|
Net margin
|
-
|
-120.81%
|
-834.57%
|
-216.48%
|
EPS
2 |
-5.926
|
-17.61
|
-85.22
|
-1.352
|
Free Cash Flow
|
-
|
-54.05
|
-26.36
|
-58.6
|
FCF margin
|
-
|
-252.09%
|
-235.68%
|
-227.43%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
11/9/21
|
5/24/22
|
3/28/23
|
Fiscal Period: December |
2022 Q2
|
---|
Net sales
|
-
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
1 |
-12.51
|
Net margin
|
-
|
EPS
2 |
-0.1700
|
Dividend per Share
|
-
|
Announcement Date
|
8/15/22
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
37.9
|
54.9
|
Net Cash position
1 |
29.3
|
35.7
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.4665
x
|
-0.4716
x
|
Free Cash Flow
|
-
|
-54.1
|
-26.4
|
-58.6
|
ROE (net income / shareholders' equity)
|
-
|
-45.5%
|
-257%
|
592%
|
ROA (Net income/ Total Assets)
|
-
|
-14.5%
|
-34.2%
|
-61%
|
Assets
1 |
-
|
178.3
|
272.6
|
91.45
|
Book Value Per Share
2 |
-56.20
|
-68.20
|
-137.0
|
-0.3400
|
Cash Flow per Share
2 |
16.90
|
22.30
|
11.80
|
0.1000
|
Capex
1 |
10.5
|
32.2
|
19.9
|
9.12
|
Capex / Sales
|
-
|
150.23%
|
178.07%
|
35.39%
|
Announcement Date
|
11/9/21
|
11/9/21
|
5/24/22
|
3/28/23
|
|
1st Jan change
|
Capi.
|
---|
| +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|